Full metadata record
DC FieldValueLanguage
dc.contributor.authorHsieh, Li-Lingen_US
dc.contributor.authorEr, Tze-Kiongen_US
dc.contributor.authorChen, Chih-Chiehen_US
dc.contributor.authorHsieh, Jan-Singen_US
dc.contributor.authorChang, Jan-Gowthen_US
dc.contributor.authorLiu, Ta-Chihen_US
dc.date.accessioned2014-12-08T15:24:10Z-
dc.date.available2014-12-08T15:24:10Z-
dc.date.issued2012-10-09en_US
dc.identifier.issn0009-8981en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.cca.2012.04.029en_US
dc.identifier.urihttp://hdl.handle.net/11536/16808-
dc.description.abstractBackground: The identification of KRAS, BRAF, and PIK3CA mutations before the administration of anti-epidermal growth factor receptor therapy of colorectal cancer has become important The aim of the present study was to investigate the occurrence of KRAS, BRAF, and PIK3CA mutations in the Taiwanese population with colorectal cancer. This study was undertaken to identify BRAF and PIK3CA mutations in patients with colorectal cancer by high-resolution melting (HRM) analysis. HRM analysis is a new gene scan tool that quickly performs the PCR and identifies sequence alterations without requiring post-PCR treatment Methods: In the present study, DNAs were extracted from 182 cases of formalin-fixed, paraffin-embedded (FFPE) colorectal cancer samples for clinical KRAS mutational analysis by direct sequencing. All the samples were also tested for mutations within BRAF V600E and PIK3CA (exons 9 and 20) by HRM analysis. Results: The results were confirmed by direct sequencing. The frequency of BRAF and PIK3CA mutations is 1.1%, and 7.1%, respectively. Intriguingly, we found that nine patients (4.9%) with the KRAS mutation were coexistent with the PIK3CA mutation. Four patients (22%) without the KRAS mutation were existent with the PIK3CA mutation. Two patients (1.1%) without the KRAS mutation were existent with the BRAF mutation. Conclusions: In the current study, we suppose that HRM analysis is rapid, feasible, and powerful diagnostic tool for the detection of BRAF and PIK3CA mutations in a clinical setting. Additionally, our results indicated the prevalence of KRAS. BRAF, and PIK3C4 mutational status in the Taiwanese population. (C) 2012 Elsevier B.V. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectColorectal canceren_US
dc.subjectKRAS geneen_US
dc.subjectBRAF geneen_US
dc.subjectPIK3CA geneen_US
dc.subjectDirect sequencingen_US
dc.subjectHigh-resolution meltingen_US
dc.titleCharacteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese populationen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.cca.2012.04.029en_US
dc.identifier.journalCLINICA CHIMICA ACTAen_US
dc.citation.volume413en_US
dc.citation.issue19-20en_US
dc.citation.spage1605en_US
dc.citation.epage1611en_US
dc.contributor.department生物資訊及系統生物研究所zh_TW
dc.contributor.departmentInstitude of Bioinformatics and Systems Biologyen_US
dc.identifier.wosnumberWOS:000307924000032-
dc.citation.woscount15-
Appears in Collections:Articles


Files in This Item:

  1. 000307924000032.pdf